Ebastine


Generic Medicine Info
Administration
May be taken with or without food.
Special Precautions
Patient with cardiac risks (e.g. long QT syndrome, hypokalaemia, treatment with agents known to increase QT interval). Concomitant use with CYP3A4 inhibitors. Severe hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness or sometimes dizziness; if affected, do not drive or operate machinery.
Adverse Reactions
Cardiac disorders: Rarely, palpitation, tachycardia. Gastrointestinal disorders: Dry mouth. Rarely, dysgeusia, abdominal pain, nausea, dyspepsia, vomiting. General disorders and administration site conditions: Asthenia. Hepatobiliary disorders: Rarely, hepatitis, cholestasis. Immune system disorders: Rarely, hypersensitivity reactions (e.g. angioedema, anaphylaxis). Investigations: Rarely, abnormal LFTs. Nervous system disorders: Headache, drowsiness. Rarely, dizziness, hypoesthesia. Psychiatric disorders: Rarely, nervousness, insomnia. Reproductive system and breast disorders: Rarely, menstrual disorders. Respiratory, thoracic and mediastinal disorders: Pharyngitis, sinusitis, epistaxis.
Drug Interactions
Increased plasma levels and risk of QTc interval prolongation with ketoconazole, itraconazole and erythromycin. Plasma concentrations and antihistamine effects may be decreased by rifampicin.
CIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AX22 - ebastine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by CIMS based on ebastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in